Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT03153319Phase 1/2Active Not Recruiting
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
PrincipalinvestigatorStart date: 2017-06-05

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

The Lundquist Institute at Harbor-UCLA Medical Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Chester B. Whitley, M.D., Ph.D.

University of Minnesota

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

Tippi C MacKenzie, MD

University of California, San Francisco

Moderately Similar
2 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

Lynda E Polgreen, MD, MS

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Moderately Similar
2 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI

Worked with same sponsors:

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Similarity Score30%

Ashley Schneider

University of Minnesota

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

Paul Harmatz, M.D.

Oakland Children's Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

Heather Lau, M.D.

New York University

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

Paul Orchard, MD

Masonic Cancer Center, University of Minnesota

Moderately Similar
9 trials

Shared therapeutic areas:

Mucopolysaccharidosis VIMucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Michal Inbar-Feigenberg, M.D.

Hospital for Sick Children, Toronto, Ontario, CA

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score30%

K. Scott Baker

Fairview University Medical Center

Related
3 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis VI
Similarity Score20%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis VI
Similarity Score20%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT03153319Phase 1/2PrincipalInvestigator

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Active Not Recruiting

All 1 trials loaded